Vor Bio's Board of Directors offers expert global biotechnology experience and perspectives

Robert Ang, MBBS, MBA, is President and CEO at Vor Bio since 2019. Prior to Vor Bio, Robert gained operational experience focused on strategy and business development through roles at Neon Therapeutics (now BioNTech), Bavarian Nordic, and Cadence Pharmaceuticals (now Mallinckrodt). Robert also has biotech venture capital experience at Frazier Healthcare Ventures, where he invested in companies such as Incline Therapeutics (now Novartis) and Alnara Pharmaceuticals (now Eli Lilly), and strategy consulting experience at the Boston Consulting Group. He also has general surgery training and his clinical practice centered around soft tissue surgery with an emphasis on solid organ transplants. He received his medical degree at the University of Western Australia and has an MBA with Honors from Columbia Business School. Robert also serves as an independent director at the early-stage cancer immunotherapy company Enara Bio, a member of the Board of Directors and the Executive Committee of the Alliance for Regenerative Medicine, and a member of the Healthcare and Pharmaceutical Management Advisory Board of Columbia Business School.

Daniella Beckman has deep financial and operational experience across the biotechnology industry, having worked with both private and publicly traded companies throughout her career. At Tango Therapeutics, Daniella oversees finance, investor relations, and business development. Prior to joining Tango, she was a consultant to early-stage biotechnology companies, leading financial activities and building companies’ financial infrastructures. She also served as Interim Chief Financial Officer for Neon Therapeutics. Previously, Daniella was Chief Financial Officer of Idenix Pharmaceuticals, responsible for finance, investor relations, and IT until it was acquired by Merck in 2014. Earlier in her career, she held various finance positions at Coley Pharmaceuticals, Biogen Idec, and PricewaterhouseCoopers (PwC). Daniella received her BA in business administration and accounting from Boston University. In addition to Vor Bio, she also serves on the Board of Directors of Blueprint Medicines.

David Lubner is a senior finance executive with more than 25 years of experience in the life sciences industry. David served as Executive Vice President and Chief Financial Officer of Ra Pharma until May 2020 following its acquisition by UCB. Prior to Ra Pharma, he was Senior Vice President and Chief Financial Officer of Tetraphase Pharmaceuticals and was previously Chief Financial Officer of PharMetrics Inc., a leading patient-based pharmacy and medical claims data informatics company. He was also Chief Financial Officer at ProScript, where Velcade® (bortezomib), a therapy widely used for the treatment of the blood cancer multiple myeloma, was discovered. David serves on the Board of Directors of Dyne Therapeutics, Therapeutics Acquisition Corp. (Nasdaq: TXAC), Gemini Therapeutics, and Ichnos Sciences. A Certified Public Accountant, Mr. Lubner received his BS in business administration from Northeastern University and an MS in taxation from Bentley University.

Bill Lundberg, MD is a medical oncologist with more than two decades of experience managing and leading biotechnology research and development. Bill is President and CEO at Merus, a clinical-stage oncology company developing innovative, full-length multispecific antibodies. Prior to joining Merus, he served as Chief Scientific Officer at CRISPR Therapeutics, where he was responsible for establishing and growing research and development in the United States and oversaw CRISPR’s first CRISPR-based product from inception to regulatory filing for clinical trials. Bill was previously Director and Chief Medical Officer of Taligen Therapeutics and Vice President and Head of Translational Medicine at Alexion Pharmaceuticals, where he oversaw R&D from discovery through early clinical development. Prior to this, he held roles of increasing responsibility in drug development and medical affairs at Xanthus (acquired by Antisoma), Wyeth (now Pfizer), and Genzyme. Bill received an MD from Stanford University School of Medicine, an MBA from Isenberg School of Management and a BS from Massachusetts Institute of Technology. He completed postdoctoral training at the Whitehead Institute/MIT and clinical training in medicine and medical oncology from Harvard and the Dana-Farber Cancer Institute.

Fouad Namouni, MD brings more than 20 years of oncology and cancer immunotherapy drug development expertise, as well as clinical experience as a pediatric oncologist. Since September 2020, he has served as President of Research & Development at Blueprint Medicines, providing key leadership as the company built a fully integrated global business and overseeing all aspects of research and development across a broad pipeline of innovative medicines in oncology/hematology and allergy/inflammation. Prior to joining Blueprint Medicines, Fouad served in leadership roles at Bristol-Myers Squibb (BMS) since 1999, including as the global development lead for the company’s practice-changing cancer immunotherapy franchise. From August 2016 to April 2020, he served as Senior Vice President and Head of Oncology Development, with responsibility for driving product development plans from early-stage clinical development through commercialization across a portfolio of nearly 30 drug candidates. Previously, he served as Head of Global Medical Affairs overseeing 1,700 employees worldwide from September 2015 to September 2017, and he served as Head of Development at BMS for Opdivo® (nivolumab) and Yervoy® (ipilimumab), immunotherapy medications used in the treatment of cancer, from January 2011 to September 2015. Prior to that, he held roles of increasing responsibility within BMS. He holds an MD from the University of Annaba Medical School in Algeria and a Pediatrics degree from Université Rene Descartes in Paris, France. In addition, he received a Pediatric Oncology and Hematology degree and an MS in clinical and experimental pharmacology from Université Paris-Sud in France.

Opdivo® and Yervoy® are registered trademarks of Bristol-Myers Squibb Company.

Matt Patterson is a biotechnology executive with more than 30 years of experience in the research, development, and commercialization of innovative therapeutics. Matt most recently served as Chairman and CEO of Iris Medicine, Inc. from January 2022 until April 2024. In 2012 Matt co-founded Audentes Therapeutics and served as Chief Executive Officer from the Company’s inception until its acquisition by Astellas Pharma Inc. in January 2020. Matt was also Chairman of the Board of Directors at Audentes and formerly served as President until May 2018. Previously Matt worked for Genzyme Corporation, BioMarin Pharmaceutical, and Amicus Therapeutics. Prior to Audentes he was an Entrepreneur-In-Residence with OrbiMed.

Matt is Chairman of the Board of Directors at Remix Therapeutics, Inc. He also served as a member of the Board of Directors of the Alliance for Regenerative Medicine (ARM), the international advocacy organization representing the gene and cell therapy and broader regenerative medicine sector, from 2015-2021, and was Chairman in 2019 and 2020. Matt received his bachelor’s degree in biochemistry from Bowdoin College.

Josh Resnick, MD is a Managing Director at RA Capital Management. Josh’s primary responsibility at RA Capital is to lead early-stage private investments and oversee the creation of new companies developing drugs, medical devices, diagnostics, and research tools. He has more than 15 years of experience in investing, company formation, and company leadership across all stages of drug development, from discovery through commercialization. He was previously Co-Lead of SV Health Investors’ U.S. biotech practice where he was responsible for SV’s U.S. venture creation activities, including its incubator, Brahma Discovery. Before SV, Josh was President and Managing Partner at MRL Ventures Fund, the early-stage therapeutics-focused corporate venture fund within Merck & Co. Prior to MRL Ventures, he was a Venture Partner with Atlas Venture and a Partner at Prism Venture Partners, focusing on company formation and seed and Series A investing. Josh is a faculty member at Harvard Medical School and an attending physician in the Department of Emergency Medicine at Brigham and Women’s Hospital. He holds a BA in chemistry from Williams College, an MD from the University of Pennsylvania School of Medicine, and an MBA from the Wharton School of Business.